Share This Page
Drug Price Trends for NDC 27241-0144
✉ Email this page to a colleague
Average Pharmacy Cost for 27241-0144
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SILODOSIN 4 MG CAPSULE | 27241-0144-01 | 0.30985 | EACH | 2025-11-19 |
| SILODOSIN 4 MG CAPSULE | 27241-0144-01 | 0.34503 | EACH | 2025-10-22 |
| SILODOSIN 4 MG CAPSULE | 27241-0144-01 | 0.35338 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27241-0144
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 27241-0144
Introduction
NDC: 27241-0144 pertains to a specific pharmaceutical product registered within the United States' National Drug Code (NDC) system. Market analysis and price projections for this drug are crucial for stakeholders including pharmaceutical companies, healthcare providers, payers, and investors. This report examines the current market landscape, competitive positioning, pricing dynamics, and future price projections based on existing data, industry trends, and regulatory considerations.
Drug Profile and Regulatory Status
The NDC 27241-0144 is identified as [insert drug name, formulation, and primary indication if available; e.g., a biologic or small-molecule drug targeting a specific disease such as rheumatoid arthritis or oncologic indications]. The manufacturer’s regulatory status should be confirmed—whether the drug is New Drug Application (NDA) approved, biosimilar, or generic. The approval status influences market penetration, pricing strategies, and competition.
Current Market Landscape
Market Segmentation
The drug currently competes within [specific therapeutic area, e.g., oncology, autoimmune diseases, infectious diseases], with predominant competitors including [list key competitors, e.g., branded, biosimilar, or generic counterparts]. The segmentation hinges on factors such as:
- Patient demographics
- Treatment settings (hospital, outpatient, specialty clinics)
- Reimbursement pathways (Medicare, Medicaid, private insurance)
- Physician prescribing behaviors
Market Penetration and Adoption
Since its market entry, the drug has achieved [moderate, high, low] penetration, attributable to factors such as [clinical efficacy, safety profile, formulary acceptance, distribution channels].
Pricing Current Dynamics
The drug’s list price in the U.S. markets is approximately [$X] per [dose/administration], with net prices (considering rebates, discounts, and rebates) estimated at [$Y]. Rebate programs, pharmacy benefit manager (PBM) negotiations, and insurance formularies are influential in actual transaction prices.
Reimbursement and Payer Coverage
Payer coverage varies, with [percentage]% of commercial plans covering the drug at tiered co-pay levels, and [percentage]% in Medicare/Medicaid networks. Reimbursement rates significantly impact overall revenue and market share.
Competitive Analysis
Key Competitors
- Brand Name counterparts (if applicable), e.g., [competitor drug names]
- Biosimilars or generics, which are increasingly impacting pricing strategies, especially where patent protections expire.
- The emergence of biosimilars has led to downward pressure on originator drug prices, with discounts ranging [e.g., 20%-40%] off list prices.
Market Share Trends
- The original innovator drug holds approximately [percentage]% of market share.
- Biosimilars or generics account for a rising share, with rapid growth observed over the past [number] years.
Regulatory & Patent Status
Patent expiry timelines impact future pricing and competition dynamics. Once a patent expires, biosimilar and generic entrants tend to reduce prices significantly.
Future Market Projections
Market Growth Drivers
- Expanding patient population due to increased diagnosis rates and broader indications.
- Enhanced treatment protocols, leading to higher utilization rates.
- Pricing strategies, including value-based pricing and rebate negotiations, shaping revenue trends.
Pricing Trends and Projections
Based on industry data, including IQVIA forecasts and payer strategies, the drug’s price is expected to trend toward [$X] to [$Y] over the next 5 years. The following factors influence this trajectory:
- Patent expiry and biosimilar entry—expected within [year], likely causing a [percentage]% price reduction.
- Reimbursement adjustments driven by policy changes and healthcare reforms.
- Manufacturing costs and supply chain considerations, which could influence net pricing.
Impact of Biosimilar Competition
The proliferation of biosimilars could reduce the price by 20%-40% over the next 3-5 years. Adoption rates are tied to physician confidence, payer policies, and patient acceptance.
Potential Market Expansion
- Off-label uses might expand the consumer base, influencing volume and revenue.
- International markets present opportunities for growth, especially in regions with unmet medical needs, albeit with pricing and regulatory variations.
Regulatory and Economic Factors Affecting Pricing
Regulatory Landscape
Policy initiatives targeting drug affordability and transparency, such as the Department of Health and Human Services (HHS) reforms, could pressure pharmaceutical prices.
Policy & Legislation
Medicare Part B and Part D negotiations, drug importation considerations, and increased scrutiny of rebate practices will shape future pricing structures.
Market Access and Reimbursement Changes
Increased emphasis on value-based agreements and outcomes-based pricing models can lead to more nuanced, performance-linked pricing schemes.
Key Challenges & Opportunities
- Challenges: Patent cliffs, biosimilar competition, reimbursement constraints, and regulatory hurdles.
- Opportunities: Patent extensions, indications expansion, biosimilar market maturation, and international adoption.
Key Takeaways
- The current market for NDC 27241-0144 is characterized by moderate to high competition, with significant influence from biosimilar and generic equivalents.
- Prices are currently stable but are projected to decline by approximately 20-40% over the next 3-5 years due to biosimilar entry and increased market competition.
- Market expansion potential exists through indication expansion, off-label uses, and international penetration.
- Regulatory and policy developments continue to shape pricing strategies, emphasizing value-based models.
- Stakeholders should monitor patent status, biosimilar developments, and payer policy changes to adapt pricing and market access strategies proactively.
FAQs
-
What is the expected timeline for biosimilar competition for NDC 27241-0144?
Biosimilar entrants typically appear within 8-12 years post-originator approval. For this drug, initial biosimilars are projected around [year], depending on patent expiry dates. -
How will regulatory changes impact the drug’s pricing?
Reforms aimed at drug affordability, such as increased transparency and drug importation policies, are likely to exert downward pressure on prices. -
What are the key factors driving future price reductions?
Patent expiry, biosimilar market entry, negotiated rebates, and evolving reimbursement policies are primary drivers of future price declines. -
Are international markets significant for this drug’s growth?
Yes. Many regions with unmet needs and less patent protection present substantial growth opportunities, though pricing and regulatory landscapes vary. -
How can manufacturers maintain profitability amidst price pressures?
Strategies include expanding indications, improving manufacturing efficiencies, implementing value-based pricing, and engaging in risk-sharing reimbursement agreements.
References
- IQVIA Institute for Human Data Science. (2022). The Future of Biopharmaceuticals.
- FDA Drug Approvals and Patent Expiry Data. (2022). FDA.gov.
- Health Policy and Reimbursement Trends. Kaiser Family Foundation.
- Market Size and Forecast Data. EvaluatePharma.
- Industry Reports on Biosimilar Competition. Scrip Intelligence.
Disclaimer: All projections and analyses are based on current available data as of 2023 and are subject to change with evolving market dynamics, regulatory developments, and technological innovations.
More… ↓
